ArticleMayo Clinic proceedings. Innovations, quality & outcomes2018
Interstitial Pneumonia in Psoriasis.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Prevalence of interstitial lung disease in patients with psoriatic arthritis: a systematic review and meta-analysis.Clinical rheumatology · 2026Pooled it
- Interstitial Lung Disease Induced by Monoclonal Antibodies for Psoriatic Arthritis, a Double Hit: A Case Report with a Literature and Clinical Trial Review.Pulmonary therapy · 2026Review
- Interstitial lung disease in psoriasis: A systematic review and meta-analysis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Interstitial Lung Disease: Does It Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound Monocentric Pilot Study.Journal of clinical medicine · 2025Article
- Systemic Biologic Treatment for Psoriasis in Elderly Patients.Journal of clinical medicine · 2025Article
- Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches.Scientific reports · 2025Article
- Unmasking Pulmonary Parenchymal Changes in Psoriasis Patients: A Radiological Perspective.Medicina (Kaunas, Lithuania) · 2025Article
- Deucravacitinib Improved Interstitial Pneumonia Along with KL-6 Reduction in a Patient with Psoriasis: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Prevalence and clinical features of interstitial lung disease in patients with psoriasis.BMC pulmonary medicine · 2024Article
- Psoriasis may increase the risk of idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.Respiratory research · 2024Article
- CT Patterns of Interstitial Lung Disease in Patients with Plaque Psoriasis: A Retrospective Case Series Study.Medicina (Kaunas, Lithuania) · 2023Article
- Pulmonary comorbidities in psoriasis are associated with a high risk of respiratory failure.The Journal of international medical research · 2023Article
- Article
- Interstitial lung disease associated with psoriatic arthritis: a new disease entity?Internal and emergency medicine · 2021Article
- Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.Respirology (Carlton, Vic.) · 2021Article
- Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis.PloS one · 2021Article
- REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19.The Journal of infection · 2020Article
- [Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020Article
- Organizing Pneumonia Complicated with Erythrodermic Psoriasis.Internal medicine (Tokyo, Japan) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the relationship between psoriasis and interstitial pneumonia (IP). PATIENTS AND
methodsWe analyzed the clinical data of patients with psoriasis treated with biologic agents from June 1, 2008, to June 30, 2017, retrospectively. Chest computed tomography was performed in 392 patients before treatment. The clinical characteristics and radiographic findings of these patients were evaluated.
resultsOf the 392 patients with psoriasis, IP was detected in 8 patients (2%). Bilateral ground-glass and/or irregular linear (reticular) opacity in the lower lung zone was the most common chest computed tomography finding. Five of the 8 patients with IP were treated with anti-interleukin (IL) 12/IL-23 or IL-17 antibodies, leading to decreased or stable IP activity.
conclusionInterstitial pneumonia was detected in 2% of patients with psoriasis who needed systemic treatments. Ground-glass and/or irregular linear (reticular) opacity in the bilateral lower lobes was characteristic of IP with psoriasis. The IL-23/IL-17 axis may play important roles in the pathogenesis of IP in psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.